Les travaux et les jours : la lente transformation des sociétés paysannes de l'âge du Bronze en<br />France métropolitaine

L'âge du Bronze constitue une période charnière, comprise entre le Néolithique - témoin del'éclosion et du développement des économies de production - et l'âge du Fer qui marque l'entréevers les périodes historiques. D'un point de vue économique, l'âge du Bronze ne connaît pas deruptures majeures. Cependant, le poids des héritages néolithiques, associé aux innovationstechnologiques apparues durant le millénaire et demi que dure l'âge du Bronze, va coïncider,partout en Europe, avec une accélération du Temps, qui conduit irrémédiablement vers l'Histoire.L'âge du Bronze reste synonyme de la naissance de la métallurgie et de l'usage croissant du métaldans toutes les sphères de la société

Quantum secrecy in thermal states II

In this paper we consider a scheme for cryptographic key distribution based on a variation of continuous variable quantum key distribution called central broadcast. In the continuous variable central broadcast scheme, security arises from discord present in the Hanbury Brown and Twiss effect from a thermal source. The benefit of this scheme is that it expands the range of frequencies into the microwave regime. Longer wavelengths—where the thermal photon number is higher and correlations remain robust over long distances—may even be preferable to optical wavelengths. Assuming that Alice controls the source but not the distribution of the light (e.g. satellite broadcasts), then we demonstrate that the central broadcast scheme is robust to an entangling cloner attack. We establish the security of the protocol both experimentally and theoretically

Pour en finir avec le Bronze final ? Les haches à douille de type armoricain en France

A discussion about socket armorican bronze axes datation. They are from Ha D period (VII th & VIt h century B.C.)Révision de la datation des haches à douille de type armoricain, au seul Hallstatt D (VIIe-VIe s; av. J.-C.

Spectrum and Variability of Mrk501 as observed by the CAT Imaging Telescope

The CAT Imaging Telescope has observed the BL Lac object Markarian 501 between March and August 1997. We report here on the variability over this time including several large flares. We present also preliminary spectra for all these data, for the low emission state, and for the largest flare.Comment: 4 pages, 4 figures, Late

Detection of Vhe Gamma-Rays from MRK 501 with the Cat Imaging Telescope

The CAT imaging telescope on the site on the former solar plant Themis has been observing gamma-rays from Mrk501 above 220 GeV in March and April 1997. This source is shown to be highly variable and the light curve is presented. The detected gamma-ray rate for the most intense flare is in excess of 10 per minute.Comment: 5 pages, 4 figures, Tex, contribution to 25th ICRC Durba

Observation of the Crab Nebula Gamma-Ray Emission Above 220 Gev by the Cat Cherenkov Imaging Telescope

The CAT imaging telescope, recently built on the site of the former solar plant Themis (French Pyrenees), observed gamma-rays from the Crab nebula from October 1996 to March 1997. This steady source, often considered as the standard candle of very-high-energy gamma-ray astronomy, is used as a test-beam to probe the performances of the new telescope, particularly its energy threshold (220 GeV at 20 degrees zenith angle) and the stability of its response. Due to the fine-grain camera, an accurate analysis of the longitudinal profiles of shower images is performed, yielding the source position in two dimensions for each individual shower.Comment: 5 pages, 3 figures, Tex, contribution to 25th ICRC Durba

ATP13A2 deficiency disrupts lysosomal polyamine export

ATP13A2 (PARK9) is a late endolysosomal transporter that is genetically implicated in a spectrum of neurodegenerative disorders, including Kufor-Rakeb syndrome—a parkinsonism with dementia1—and early-onset Parkinson’s disease2. ATP13A2 offers protection against genetic and environmental risk factors of Parkinson’s disease, whereas loss of ATP13A2 compromises lysosomes3. However, the transport function of ATP13A2 in lysosomes remains unclear. Here we establish ATP13A2 as a lysosomal polyamine exporter that shows the highest affinity for spermine among the polyamines examined. Polyamines stimulate the activity of purified ATP13A2, whereas ATP13A2 mutants that are implicated in disease are functionally impaired to a degree that correlates with the disease phenotype. ATP13A2 promotes the cellular uptake of polyamines by endocytosis and transports them into the cytosol, highlighting a role for endolysosomes in the uptake of polyamines into cells. At high concentrations polyamines induce cell toxicity, which is exacerbated by ATP13A2 loss due to lysosomal dysfunction, lysosomal rupture and cathepsin B activation. This phenotype is recapitulated in neurons and nematodes with impaired expression of ATP13A2 or its orthologues. We present defective lysosomal polyamine export as a mechanism for lysosome-dependent cell death that may be implicated in neurodegeneration, and shed light on the molecular identity of the mammalian polyamine transport system

Higher Yield and Fewer Weeds in Four-Species Grass/Legume Mixtures Than in Monocultures: Results from the First Year at 20 Sites of Cost Action 852

Utilisation of grass/legume mixtures instead of grass monocultures is a sensible alternative for low input, efficient agricultural systems that reduce production costs, promote environmental policy and maintain a living countryside. Consequently, widely adapted forage legumes will become increasingly important. Instability of simple grass / legume mixtures with only one grass and one legume species is a major problem (Wachendorf et al., 2001). An experiment was established in 39 sites in Europe, Australia and Canada within COST Action 852 to: (1) assess the benefits of grass / legume mixtures in terms of forage production, (2) test whether the combination of fast and slow-growing species improves the stability of the mixtures and (3) assess response patterns over a large environmental gradient

Quality-of-Life Impact of an Investigational Subunit-Adjuvanted Herpes Zoster Vaccine in Adults ≥50 Years of Age

n/

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis

Importance Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. Objective All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A] inhibitor), asunaprevir (NS3 protease inhibitor), and beclabuvir (nonnucleoside NS5B inhibitor), with or without ribavirin, was evaluated in patients with HCV genotype 1 infection and compensated cirrhosis. Design, Setting, and Participants The UNITY-2 study was conducted between December 2013 and October 2014 at 49 outpatient sites in the United States, Canada, France, and Australia. Patients were treated for 12 weeks, with 24 weeks of follow-up after completion of treatment. Adult patients with cirrhosis were enrolled in 2 cohorts: HCV treatment-naive or HCV treatment-experienced. Statistical analyses were based on historical controls; there were no internal controls. Interventions All patients received twice-daily treatment with the fixed-dose combination of daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg). In addition, patients within each cohort were stratified according to HCV genotype 1 subtype (1a or 1b) and randomly assigned (1:1) to receive double-blinded weight-based ribavirin (1000-1200 mg/d) or matching placebo. Main Outcomes and Measures Sustained virologic response at posttreatment week 12 (SVR12). Results One hundred twelve patients in the treatment-naive group and 90 patients in the treatment-experienced group were treated and included in the analysis. Enrolled patients were 88% white with a median age of 58 years (treatment-naive group) or 60 years (treatment-experienced group); 74% had genotype 1a infection. SVR12 rates were 98% (97.5% CI, 88.9%-100%) for patients in the treatment-naive group and 93% (97.5% CI, 85.0%-100.0%) for those in the treatment-experienced group when ribavirin was included in the regimen. With the fixed-dose combination alone, response rates were 93% (97.5% CI, 85.4%-100.0%) for patients in the treatment-naive group and 87% (97.5% CI, 75.3%-98.0%) for those in the treatment-experienced group. Three serious adverse events were considered to be treatment related and there were 4 adverse event–related discontinuations. Treatment-emergent grade 3 or 4 alanine aminotransferase elevations were observed in 4 patients, of which 1 had concomitant total bilirubin elevation. Conclusions and Relevance In this open-label uncontrolled study, patients with chronic HCV genotype 1 infection and cirrhosis who received a 12-week oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin, achieved high rates of SVR12